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Background: Osteoarthritis (OA) is the fastest growing cause of disability worldwide. Current treatments for OA are
severely limited and a large proportion of people with OA live in constant, debilitating pain. There is therefore an
urgent need for novel treatments to reduce pain. Synovitis is highly prevalent in OA and is associated with pain. In
inflammatory arthritides such as rheumatoid arthritis, methotrexate (MTX) is the gold standard treatment for
synovitis and has a well-known, acceptable toxicity profile. We propose that using MTX to treat patients with
symptomatic knee OA will be a practical and safe treatment to reduce synovitis and, consequently, pain.
Methods/Design: Pain Reduction with Oral Methotrexate in knee Osteoarthritis, a pragmatic phase III trial of
Treatment Effectiveness (PROMOTE) is an investigator-initiated, multi-centre, randomized, double-blind, pragmatic
placebo-controlled trial. A total of 160 participants with symptomatic knee OA will be recruited across primary and
secondary care sites in the United Kingdom and randomized on a 1:1 basis to active treatment or placebo, in
addition to usual care, for 12 months. As is usual practice for MTX, dosing will be escalated over six weeks to 25 mg
(or maximum tolerated dose) weekly for the remainder of the study. The primary endpoint is change in average
knee pain during the past week (measured on an 11-point numerical rating scale) between baseline and six
months. Secondary endpoints include other self-reported pain, function and quality-of-life measures. A health
economics analysis will also be performed. A magnetic resonance imaging substudy will be conducted to provide
an explanatory mechanism for associated symptom change by examining whether MTX reduces synovitis and
whether this is related to symptom change. Linear and logistic regression will be used to compare changes
between groups using univariable and multivariable modelling analyses. All analyses will be conducted on an
intention-to-treat basis.
Discussion: The PROMOTE trial is designed to examine whether MTX is an effective analgesic treatment for OA.
The MRI substudy will address the relationship between synovitis and symptom change. This will potentially
provide a much needed new treatment for knee OA.
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With a rapidly ageing population, osteoarthritis (OA) has
become the fastest growing cause of disability worldwide
[1,2]. Current estimates suggest that over 250 million
people across the globe are affected by OA, with a lifetime
risk for the development of knee OA of approximately
40% [1-3]. OA is characterized by chronic joint pain and
functional impairment, resulting in markedly reduced
quality of life for individuals. OA also places an enormous
burden on health services and health economies, and is
the second leading cause of absence from work [4]. The
cumulative cost of OA has been estimated to amount to
approximately 1% of gross national product [5,6].
One of the major barriers to reducing the impact of
OA, both on individuals and society, is the lack of effica-
cious therapies available to treat the symptoms of OA or
to slow the disease process and associated structural
progression. Current management guidelines for OA in-
clude pharmacological therapies such as paracetamol
and NSAIDs, and non-pharmacological therapies includ-
ing weight loss and exercise [7-9]. Although current
treatments are aimed at providing symptomatic relief,
recent studies suggest that the large majority of people
with OA live in constant pain despite use of available
therapies [10]. These therapies are also associated with
significant toxicities. In addition, because the typical OA
patient is of advanced age with multiple comorbidities,
many have contraindications to the use of traditional
OA medications. Hence, there is a pressing need to
identify alternative therapies for OA in order to tackle
this increasing problem [11,12].
There is increasing evidence, particularly from imaging
studies, of a high prevalence of synovitis (inflammation
of the synovial membrane) in OA, with abnormalities
present from the earliest stages of the disease and asso-
ciated with the presence and severity of pain [13-18].
These changes are often indistinguishable to those ob-
served in rheumatoid arthritis (RA), although they are
generally confined to more discrete regions within the
joint, generally adjacent to sites of chondropathy. In-
creased levels of pro-inflammatory cytokines (such as
tumour necrosis factor (TNF)α, interleukin (IL)-1β and
IL-6), reduced levels of anti-inflammatory cytokines
(such as IL-10 and IL-1RA), infiltration of mononuclear
cells and adaptive immune cell responses have all been
demonstrated within OA fluid and tissue, suggesting that
modulating the inflammatory response may be effective
as a treatment target for OA [19-21].
The rationale for targeting synovitis as a treatment for OA
pain is supported by previous studies of anti-inflammatory
agents. Randomized controlled trials of non-steroidal anti-
inflammatory drugs (NSAIDs) and the fewer randomized
controlled trials of intra-articular (IA) and oral corticoste-
roids have demonstrated modest, short-term pain reductionassociated with anti-inflammatory effects and reduced syno-
vitis [22-27]. However, although NSAIDs and corticosteroids
have positive short-term effects their long-term use is not
desirable, with contra-indications to their use in many
people with OA.
Disease modifying anti-rheumatic drugs (DMARDs) are
the mainstay of treatment for RA and all have anti-synovial
effects. Methotrexate ((MTX) 4-amino-10-methylfolic acid)
is the first-line treatment widely used to treat synovitis in
the inflammatory arthritides, and current evidence suggests
it is the most effective DMARD and safe for long-term use
[28]. Indications for the use of MTX have expanded in re-
cent years to include trials to reduce cardiovascular disease
(CVD) in the general population, as well as showing reduc-
tions in CVD in RA patients [29]. There is more uncer-
tainty about the benefits of MTX in other peripheral joint
arthritides such as psoriatic arthritis (PsA), however this
may reflect a lack of robust trial data [30].
MTX is a folic acid antagonist which has both an anti-
proliferative and an anti-inflammatory action. The anti-
proliferative activity of MTX is mediated through inhib-
ition of the de novo synthesis of purines and pyrimidines
by acting as a specific antagonist of folic acid. MTX was
initially used in high doses for its anti-proliferative effect
in the treatment of cancer, at doses of up to 5,000 mg
per week. At much lower doses (15 to 25 mg per week),
as used in inflammatory arthritis, MTX has an anti-
inflammatory effect by inducing an increase in adenosine
release from cells through selective inhibition of aminoi-
midazole carboxamide ribonucleotide (AICAR) transfor-
mylase, an enzyme that catalyses an intermediary step in
de novo purine biosynthesis. Extracellular adenosine is a
potent inhibitor of inflammation, suppressing the in-
flammatory functions of neutrophils, macrophages and
monocytes, dendritic cells and lymphocytes, thereby re-
ducing secretion of inflammatory cytokines, including
TNFα and IL-6, which drive synovitis [31,32].
Given the high levels of pro-inflammatory cytokines
and the evidence of immune cell infiltration into OA
joints, coupled with the strong correlations observed be-
tween synovitis and pain, there is rationale for the use of
MTX for reducing symptoms in OA. Most patients tol-
erate MTX for long-term use [33] and the use of folic
acid concomitantly with MTX reduces the incidence of
side-effects [34]. Patients undergo regular blood moni-
toring to assess for toxicity, and abnormalities in results
usually respond to a dose reduction or temporary cessa-
tion, or an increase in folic acid supplementation. Side-
effects of MTX can include gastrointestinal side-effects,
haematological abnormalities and elevated liver trans-
aminases. Side-effects resulting in discontinuation of
the drug vary in frequency from 15 to 17% [35,36], but
have been shown to reduce to 4% in the second year of
treatment [35].
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treating OA. Two small studies, one in knee OA and the
other in hand OA, have been carried out and these had
conflicting results (Figure 1 and Table 1) [37,38]. One
additional study examined the effect of MTX in calcium
pyrophosphate crystal disease (CPPD) [39]. However,
these studies included very low patient numbers and
small doses of MTX, which makes it difficult to deter-
mine whether the results are valid.
More recently, we conducted an open-label pilot study
of 30 patients with knee OA who took MTX for six
months [40]. A total of 23 patients completed the study,
20 of whom were taking a MTX dose of 15 mg/week or
more. At six months, 50% of patients had a 20% reduc-
tion in pain, whilst 37% had a 40% reduction in pain. Of
the seven participants who did not complete the study,
four withdrew due to side effects (lethargy, nausea and
headaches in three patients and thrush in one patient)
and three withdrew due to lack of response. Further evi-
dence for the potential of MTX as a therapy for OA can
be extrapolated from animal studies, with positive effects
on cartilage demonstrated in lapine models of OA
[41,42].
Taken together these clinical and experimental studies
suggest potential for MTX as a useful treatment for OA.
We propose that treating patients with symptomatic
knee OA with MTX will be a practical and safe treat-
ment to reduce synovitis and therefore reduce pain. We
believe that the preliminary data from the handful of
small studies previously conducted, including our pilot
study, strongly support the need for a well-designed,Embase: 697
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Figure 1 Overview of systematic review of methotrexate use in
osteoarthritis. Databases: PubMed, MEDLINE and Embase. Search
terms: MeSH headings #1 ‘osteoarthritis’ and #2 ‘methotrexate’.
Limits: Humans.adequately powered, randomized placebo-controlled trial
to examine fully the potential use of MTX as a treat-
ment for OA. The Pain Reduction with Oral Methotrex-
ate in knee Osteoarthritis, a pragmatic phase III trial of
Treatment Effectiveness (PROMOTE) was designed to
this end.
This paper states the objective of the PROMOTE trial,
discusses study design challenges encountered in its
planning, and outlines the resultant study design and
protocol for the PROMOTE trial.
Trial objectives
The primary objective of the trial is to determine whether
MTX reduces pain associated with knee OA as compared
to placebo. Secondary objectives of the trial are:
1. To determine whether MTX improves function,
2. To determine whether MTX improves quality of life
and
3. To determine whether MTX is a cost-effective treat-
ment for knee OA.
In addition to the main study, PROMOTE contains a
magnetic resonance imaging (MRI) substudy and a bio-
logical substudy. Patients enrolled in the main study may
opt to enrol in one, both or neither of the sub-studies.
The objective of the MRI substudy is to provide an ex-
planatory mechanism for associated symptom change by
examining whether MTX reduces synovitis, and whether
this is related to symptom change. The objective of the
biological substudy is to determine whether baseline sol-
uble immunological and inflammatory biomarkers predict
response to treatment, and whether changes in levels
occur following treatment with MTX.
Trial development
The trial was designed with key stakeholders including
rheumatologists with experience of treating OA, general
practitioners with a special interest in musculoskeletal
disease, methodologists and users with experience of
knee OA. The intention was to be pragmatic, allowing
physicians to include MTX in the overall care of patients
with knee OA and have relative flexibility in this regard,
thereby being representative of clinical practice. We
faced a number of challenges in achieving the ideal de-
sign for the PROMOTE trial which are discussed in
more detail in the relevant sections below. Key chal-
lenges included defining the dosing and dose escalation
strategy for use of MTX in OA patients, maintaining the
blind due to the well-known side-effect profile of MTX,
timing of the primary outcome, ensuring optimal recruit-
ment for a trial that is conducted in secondary care for a
condition where patients predominantly reside in primary
care and maintaining the pragmatic nature of the trial with
Table 1 Systematic review of methotrexate use in osteoarthritis
Reference n Site Treatment Outcome
de Holanda 2007
[37]
58 Knee OA Double-blind, placebo controlled, 4 months,
7.5 mg/week
No statistically significant difference between both groups
regarding WOMAC (P = 0.94), Lequèsne Algofunctional
Index (P = 0.87) and VAS (P = 0.89. No significant difference
in paracetamol consumption between both groups, however,
there was tendency to increased consumption in the
placebo group.
Pavelka 2006 [38] 21 Erosive hand
OA
Open label, 10 mg of MTX orally
for two months
Significant decrease of pain after 2 months of
treatment (54.4 ± 17.0 mm versus 39.7 ± 19.6 mm, P <0.01)
and stiffness (28.8 ± 24 min versus 21.8 ± 19.1 min, P <0.01)
Chollet-Janin 2007
[39]
5 CPPD Open label, 5 to 20 mg/week Clinical response in all 5 patients with significant reduction in
pain intensity, swollen and tender joint counts and mean
improvement time of 7.4 weeks
CPPD, calcium pyrophosphate deposition disease; MTX, methotrexate; OA, osteoarthritis; VAS, visual analogue scale; WOMAC, Western Ontario and McMaster
Osteoarthritis Index.
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the validity of the primary pain outcome.
Methods/Design
The PROMOTE trial is an investigator-initiated, multi-
centre, 160 patient, randomized placebo-controlled trial
to compare the reduction in pain associated with knee
OA with MTX as compared to placebo. Participants will
be randomized on a 1:1 basis to MTX or placebo, and
treatment will be for 12 months.
Population
All adults with symptomatic radiographic knee OA and
inadequate response or toxicity to their existing medica-
tion (to include paracetamol, NSAIDs or opioid).
Intervention and comparator
Participants will be randomized to receive either over-
encapsulated MTX 2.5 mg tablets (packed with microcrystal-
line cellulose (Sharp Clinical Services (UK) Ltd, Crickhowell,
Wales)) or placebo (matching capsules packed with micro-
crystalline cellulose (Sharp Clinical Services (UK) Ltd,
Crickhowell, Wales)).
Choice of dosing for methotrexate in patients
with osteoarthritis
MTX is currently used in RA with a maximum dose of
25 mg per week. Previous small studies in OA have used
lower doses than those used in RA [37,38]; however to
alleviate concerns around inefficacy due to inadequate
dosing, we will follow current guidelines for use of MTX
in RA as the model for the PROMOTE trial. Participants
will be prescribed 10 mg MTX or placebo weekly for
two weeks, followed by 15 mg weekly for two weeks,
20 mg weekly for two weeks and 25 mg weekly for the
remainder of the study if there is no toxicity as deter-
mined at the physician’s discretion [43,44]. In practice,
slower dose escalation may be necessary in some partici-
pants, and deviations from this protocol (for exampleescalation by 2.5 mg every two weeks) will be permitted
at the clinician’s discretion to bring participants to the
maximum tolerated dose as closely in line with the
stated strategy as possible.
If participants show toxicity to MTX upon dose escal-
ation the dose will be dropped to the maximum toler-
ated dose (minimum dose, 7.5 mg/week) and this will be
maintained for the duration of the study. In our pilot
study of MTX in OA, 20 of the 23 participants complet-
ing the study did so on a dose of 15 mg or more. Dose
reduction (to 7.5 to 12.5 mg) was required in four partic-
ipants; one due to renal impairment and three due to
side effects (nausea, headache and sore roof of mouth),
all of which improved upon dose reduction. Participants
who are intolerant of oral MTX will not be switched to
subcutaneous MTX (a common practice for RA), due to
complexities in maintaining the blind.
All participants will be routinely reminded and en-
couraged to comply with the prescribed dose of investi-
gational medicinal product (IMP). However, given the
long half-life of MTX, those who miss doses of IMP will
be allowed to restart medication if they so wish, and will
not be handled differently during the course of follow-
up. For the purposes of analysis, a participant missing
more than four doses of MTX within any three-month
period will be counted as a ‘non-complier’.
Non-investigational medicinal product
All participants will be prescribed oral folic acid 5 mg
tablets to be taken on the six consecutive days after tak-
ing the weekly MTX or placebo dose. Folic acid supple-
mentation has been shown to ameliorate side effects
associated with MTX’s activity as an antagonist of folic
acid metabolism [45].
Concomitant medication
In order to maintain the pragmatic nature of the trial, there
are no restrictions written into the protocol with regard to
concomitant analgesic medications. All participants, whether
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treatments for knee OA that they are taking at their screen-
ing visit for the duration of the trial. Investigators will be re-
sponsible for the overall management of a participant’s
medication, and will ask participants to avoid changing their
analgesic or anti-inflammatory medication for the duration
of the trial. However, if a participant is experiencing in-
creased pain and requires an increase in the dose of analge-
sics then the use of paracetamol, topical or oral NSAIDs or
opioids, or a combination of these will be permitted, but the
reason for the dose increase and the dose used will be docu-
mented. The choice of medications and doses to be used lie
with the principal investigator and clinicians working at
study sites in order to ensure that treatment for participants
in both groups is optimized. Participants will be permitted
to continue current use of chondroitin and glucosamine,
provided the dose has been stable for three months at study
entry; however their use must be clearly documented in the
case report form (CRFChondroitin or glucosamine therapy
will not be commenced during the duration of the trial.
Chronic NSAID and opioid use days in the last three
months) will be included as a covariate in the analysis.
The exception to this rule is corticosteroid use, since cor-
ticosteroids may have a significant effect on a participant’s
experience of pain, to the point of affecting response to the
primary outcome. Whilst there will be no overall restriction
on the use of corticosteroids, the protocol provides guid-
ance to investigators on the use of corticosteroids in order
to minimise effects on the primary outcome, as detailed
below. Participants will be asked not to use corticosteroids
(oral, intravenous, IA or intra-muscular) between months
three to six of the trial (three months before the primary
endpoint). In months zero to three and six to 12 a single
IA corticosteroid (in a non-knee joint) and up to one week
of oral corticosteroids will be permitted. If corticosteroids
are deemed necessary for medical reasons then their date
of use, dose, route and indication must be clearly docu-
mented in the CRF. Patients will be offered the option of a
rescue IA corticosteroid injection to their signal knee after
the six-month visit of the trial if their symptoms are intoler-
able despite current medication. Corticosteroid use is ul-
timately at the discretion of the principal investigatoror
study physician. All steroid use must be notified to the
PROMOTE trial team centrally, but this will not affect the
participant’s continued follow-up in the trial.
Outcome measures
The PROMOTE trial will examine a range of clinical,
imaging and quality-of-life and economic outcomes, in
line with the objectives listed.
Clinical outcome measures
The primary endpoint of the study will be change in
‘average overall knee pain severity over the previousweek’ (as graded on a zero to 10 numerical rating scale
(NRS)) between baseline and six months (24 weeks). An
NRS was chosen to measure pain as they have been
found to be reliable and to demonstrate good face and
criterion validity, and they are recommended as a core
outcome measure for chronic pain clinical trials by the
Initiative on Methods, Measurement, and Pain Assess-
ment in Clinical Trials (IMMPACT) [46-50].
The timing of the primary outcome at six months was
defined due to the slow-acting nature of MTX. Studies
in RA have found that several months of treatment may
be required before any symptomatic effect is noted
[43,44]. Our own recent study of MTX versus MTX plus
etanercept in RA, in which the MTX arm used the same
dosing schedule as that planned for the PROMOTE trial,
found that approximately 20% of participants in the
MTX arm showed a major clinically significant response
(tender and swollen joint count of zero) at three months,
with this rising to 29% at six months and 33% at
12 months. In our pilot study of MTX in OA, the reduc-
tion in 48-hour pain VAS scores was significantly greater
at 24 weeks (median (interquartile range (IQR)) reduc-
tion of 27 mm (four to 38)) than at 12 weeks (median
(IQR) reduction of 9 mm (−1 to 36)).The dose escalation
schedule for the PROMOTE trial requires a minimum
of six weeks to reach maximum dosage, and in reality
we know that it can often take longer than this to es-
calate the dosage. Taken together with evidence from
the RA literature, which suggests that at least two to
three months may be required at maximal dose for
symptomatic benefit to be achieved, a primary out-
come earlier than six months may fail to fully capture
the clinical response to treatment. However, add-
itional outcomes will be recorded at three months
(12 weeks) to identify early response, and nine and
12 months (36 and 48 weeks) to capture longevity of
response.
Secondary outcome measures include self-reported
assessment of pain and function using 11-point NRSs to
assess worst knee pain severity, global disease activity
and satisfaction with knee function over the past week,
together with the pain, function and stiffness subscales
of the Western Ontario McMaster Universities Index
(WOMAC version 3.1) and the Intermittent and Con-
stant Osteoarthritis Pain scale (ICOAP). Depression and
anxiety will be assessed using the Hospital Anxiety and
Depression Scale (HADS). These measures are outlined
further in Table 2.
Quality-of-life and health economic outcome measures
Utility will be measured using the EuroQol (EQ-5D-5 L),
deriving quality-adjusted life years (QALYs) for each par-
ticipant. Disease-specific quality-of-life measures are
listed in Table 2.
Table 2 Outcome measures
Month(s)
0 3 6 9 12
Primary outcome
Average overall knee pain severity over the
previous week (0 to 10 NRS)
✓ ✓ ✓ ✓ ✓
Secondary outcomes
Imaging assessments:
MRI of signal knee ✓ ✓
Clinical assessments:
Knee examination ✓
Self-reported questionnaires:
WOMAC 3.1 (pain, stiffness and
function) - five-point Likert scale
✓ ✓ ✓ ✓ ✓
ICOAP ✓ ✓ ✓ ✓ ✓
11-point NRS for: ✓ ✓ ✓ ✓ ✓
Worst knee pain severity,/ global disease activity and
pain in other joints over the past week
Satisfaction with knee function over the past 2 days
Knee pain, aching or stiffness over the past month
(no days to all days)
Globala improvement in knee problem, pain and
function
✓ ✓ ✓ ✓
Pain elsewhere (pain manikin) ✓ ✓ ✓ ✓ ✓
Duration of knee pain over the past 12 months
(<7 days, 1 to 4 weeks, >1 month, <3 months or
>3 months)
✓
Onset of knee pain (last 12 months, 1 to 5 years, 5 to
10 years or 10 years or more)
✓
Quality of life: SF-12 v2 and OAQoL [40] ✓ ✓ ✓
EuroQol EQ-5D [41,42] ✓ ✓ ✓
Depression and anxiety: HADS ✓ ✓ ✓
Resource use: ✓ ✓ ✓
Demographics and medical history ✓
Brief medication questionnaire ✓ ✓ ✓ ✓
Concomitant medicationb ✓ ✓ ✓ ✓ ✓
Adverse eventsb ✓ ✓ ✓ ✓
aA six-point Likert scale: completely better, much better, better, no change,
worse or much worse. bAlso recorded at 1 and 2 months. HADS, Hospital
Anxiety and Depression Scale; ICOAP, Intermittent and Constant Osteoarthritis
Pain; NRS, numerical rating scale; OAQoL, Osteoarthritis Quality of Life Scale;
VAS, visual analogue scale; WOMAC, Western Ontario McMaster
Universities Index.
Table 3 Magnetic resonance imaging acquisition protocol
Plane Sequence Slice Thickness
Sagittal T1 SE 2 mm
Sagittal PD FSE TE = 40 Fat Saturated 3 mm
Sagittal T2 FSE Fat Saturated 3 mm
Coronal PD FSE TE = 40 Fat Saturated 3 mm
Coronal STIR 4 mm
Axial PD FSE TE = 40 Fat Saturated 3 mm
Post gadolinium:
Sagittal T1 3D SPGR Fat Saturated/Water Excitation Isotropic
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Gadolinium-enhanced 1.5/3.0 T MRI of the signal knee
will be performed at baseline and six months according
to the protocol outlined in Table 3. All images will be
quality controlled by an experienced musculoskeletal
radiologist within two weeks of acquisition to ensure
that the image quality is sufficient for scoring purposes.
MRIs will be centrally scored semi-quantitatively and
quantitatively at the end of the study. Semi-quantitativescoring will be conducted using the MRI Osteoarthritis
Knee Score (MOAKS) [51]. Images will be quantitatively
scored using statistical shape modelling technology to
automatically quantitate total and compartmental syn-
ovial volume, total and compartmental bone shape and
other relevant features including cartilage morphology
[52].
Sample size
The standard deviation used in the sample size calculation
is an estimate from previous studies. The internal pilot
study will be used to re-estimate the sample size required
and increase the recruitment target if necessary.
A data-driven analysis which related change on an NRS
with patient global assessment of change using data from
10 similar trials of chronic pain showed that a 30% change,
or two points on the NRS was related to change of clinical
importance in chronic pain. The correlation between clin-
ician and patient global assessment of change was high in
this review, and the large sample size used underscores
the external validity of these estimates [53]. This estimate
of a two-point change on a NRS being associated with a
‘much better’ improvement was also seen in a prospective
cohort of patients with chronic musculoskeletal pain [54].
In a recent placebo-controlled, 121 patient, OA knee
trial using an 11-point pain NRS as the primary outcome,
the mean (standard deviation (SD)) baseline pain score
was 6.1 (2.1) in the control group, 7.7 (1.4) in the placebo
group, 7.1 (2.8) in treatment group A and 6.7 (2.5) in
treatment group B [55]. In a separate 73 patient OA knee
trial, the mean (SD) baseline pain score was 4.0 (2.1) in
group A and 4.3 (1.9) in group B. At 12 months, the mean
(SD) within-group difference was 0.9 (2.1) for group A
and 1.3 (2.4) for group B [56]. For the sample size calcula-
tion an SD of 4 is used as a conservative estimate.
The expected consistency in baseline pain among our
trial population allows the use of raw change in score,
rather than percentage change [53]. In order to detect a
two-point change, with an assumed SD of 4 (80% power
and 5% significance level), 64 participants per arm are
required. Allowing for a conservative 20% dropout rate,
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cruited into the study.
Trial procedures
Ethical approval for the study has been granted by the
Leeds West Research Ethics Committee (reference num-
ber 13/YH/0279). Informed written consent will be ob-
tained from all participants.
Participant recruitment strategy
Since knee OA is primarily managed within primary
care, our recruitment strategy must enable a clear inter-
face between primary care centres and the secondary
care sites at which trial activity will take place. Relevant
Clinical Commissioning Group (CCG) approvals will be
obtained to enable primary care sites to act as Patient
Identification Centres (PICs), with potentially eligible pa-
tients referred on to local secondary care study teams.
A total of 160 subjects with symptomatic knee OA will
be recruited and randomly allocated to either the treat-
ment or placebo control group. Recruitment methods
will include advertisements through the local media and
community groups, invitations to previous study partici-
pants who have given their consent to be contacted re-
garding future research projects and liaisons with
musculoskeletal physicians, general practitioners and al-
lied health professionals. Recruitment will be initiated at
all sites as soon as local approvals are in place, therefore
recruitment to the pilot phase may occur from multiple
sites. There will be no pause in recruitment once 30 pa-
tients are recruited, as the outcome from the analysis of
the pilot phase will be to either continue to the planned
numbers or to increase the planned sample size.
Informed consent and participant confidentiality
Informed consent will be obtained before patients are
screened for participation in the PROMOTE trial. The
right of the patient to refuse consent without giving rea-
sons will be respected. Further, the patient will remain
free to withdraw from the study at any time without giv-
ing reasons and without prejudicing any further treat-
ment. The written consent will be obtained by an
appropriately delegated clinician who is, by education
and experience, qualified to do so, and who has signed
and dated the staff authorization and delegation log. The
process of obtaining written consent will be clearly doc-
umented in the patient’s medical notes. Patient confiden-
tiality will be guaranteed at all times, in line with the
requirements of the United Kingdom Data Protection
Act 1998 and NHS regulations.
Eligibility criteria
Participants must meet the inclusion and exclusion cri-
teria (shown in Table 4) in order to participate. Thesewill be assessed at the screening visit (Figure 2). Poten-
tial participants who are deemed ineligible at screening
will be allowed a second screening visit if the reason for
ineligibility is a temporary status (for example, recent
corticosteroid injection; Table 4).
Identical over-encapsulated MTX and placebo capsules
will be produced to ensure allocation concealment.
Upon production, study medication will be packed into
bulk numbered bottles according to a randomization
schedule. This will be prepared by the contract manufac-
turer using a computerized random number generator,
thereby guaranteeing full allocation concealment. Study
medication will be issued in numerical order by the
pharmacy. Participants in each site will be randomly
assigned to the intervention arm or the placebo arm in a
ratio of 1:1, and the randomization will be double-blind.
Blinding
Investigators and participants will remain blinded
throughout the trial. Emergency unblinding will be
allowed in limited situations that impact on the safety of
study participants. Code-break envelopes for the full
randomization schedule will be maintained by the Leeds
General Infirmary pharmacy, and pharmacies at other
sites will hold code-break envelopes for their respective
participants. A 24-hour code-break telephone line will
also be established in case of the need for emergency
out-of-hours unblinding. Participants who are unblinded
will be withdrawn from treatment but will continue to
be followed as per the planned follow-up schedule, un-
less they request to fully withdraw from the trial.
Maintaining the treatment blind
Given the possible toxicities related to MTX, there is po-
tential for investigators reviewing blood results to be-
come aware of treatment. Therefore, patient-reported
outcomes will be completed before any changes in dose
or results of blood monitoring are discussed with partic-
ipants. Where possible, members of staff with knowledge
of blood results will not be responsible for administering
patient questionnaires.
Data collection
All data will be collected on standardized CRFs, which
will be completed by site staff, verified by the principal
investigator, and returned to the clinical trials unit for
data entry. Study sites will also return a patient non-
identifiable participant log and study drug dispensing log
to the clinical trials unit.
Patient reported, clinical and imaging assessments
In addition to the patient-reported measures of pain,
function and quality-of-life and imaging outcome
measures described above and outlined in Table 2, a
Table 4 Eligibility criteria
Inclusion criteria Exclusion criteria
Fulfil clinical ACR Criteria for knee OA The presence of any inflammatory arthritis (such as gout, reactive arthritis,
rheumatoid arthritis, psoriatic arthritis, seronegative spondyloarthropathy,
previous diagnosis of pseudogout in target joint with proven crystals on
joint aspiration or elevated CRP at time of knee arthritis flare) or
fibromyalgia.
Knee pain on most days in the last 3 months
Knee pain is the predominant pain condition Use of intra-articular (IA) hyaluronic acid in the signal knee within the
4 months preceding enrolment in the studya
Insufficient pain relief from, inability to tolerate or contra-indication to
oral and/or topical NSAIDs and/or opioids. Moderate to severe pain of
the signal knee as defined by a score of ≥40 mm on a VAS (0 to
100 mm) using the question ‘On average, how would you rate your
knee pain during the last 3 months?’.
Use of IA, IM (intra-muscular) or oral corticosteroids in the 3 months
preceding enrolmenta
Use of other anti-synovial agents (such as hydroxychloroquine or
sulphasalazine) in the 2 months preceding the studya
Significant knee injury or any knee surgery within the 6 months
preceding enrolment in the studya
Patient able to identify a ‘signal’ painful knee (either the most
painful knee or selected from equally painful knees)
The presence of non-OA causes of pain in the signal knee, such as
referred hip pain, osteonecrosis or radicular spinal pain
A previous radiograph (X-ray) of the signal knee within the
last 2 years with changes consistent with tibiofemoral OA
Commencement of physiotherapy or non-pharmacological knee OA
treatment in the 2 months preceding the studya
No change in the average weekly dose of oral or topical
analgesics (including NSAIDs) for at least 4 weeksa
A history of partial or complete joint replacement surgery in the signal
knee at any time, listed for knee surgery or anticipating knee surgery
during the study period
Has used chondroitin or glucosamine for at least 3 months with no
change to the average weekly dose, is not using or is willing to stop
using if recently starteda
Women who are pregnant, breast-feeding or men or women planning
pregnancy within 18 months after screening (approximately 6 months
following last study medications)
All male and female subjects biologically capable of having children
must agree to use a reliable method of contraception for the duration
of the study and 24 weeks after the end of the study period. Acceptable
methods of contraception are surgical sterilisation, oral, implantable
or injectable hormonal methods, intrauterine devices or barrier
contraceptives.
Use of any investigational (unlicensed) drug within 1 month prior to
screening or within 5 half-lives of the investigational agent, whichever
is longera
Have current signs or symptoms of severe, progressive or uncontrolled
renal, hepatic, haematological, gastrointestinal, endocrine, pulmonary,
cardiac, neurologic or cerebral disease
If female have potential for child bearing then a negative pregnancy
test must be performed prior to starting treatment.
Poor tolerability of venepuncture or lack of adequate venous access
for required blood sampling during the study period
The patient must be able to adhere to the study visit schedule and
other protocol requirements
Uncontrolled disease states, such as moderate or severe asthma, COPD
or inflammatory bowel disease, where flares are commonly treated
with oral or parenteral corticosteroids, or recurrent infections
The patient must be capable of giving informed consent and the
consent must be obtained prior to any screening procedures
Unwilling to keep alcohol intake to below the recommended maximum
daily limit during the trial (2 units per day for women, 3 units per
day for men)
All patients must have had a chest radiograph (X-ray) within
the last 6 months
Planned need for live vaccination during 12 months of study
(for example for foreign travel) with exception of Zostavax®, which
is permissible
Aged ≥18 years Melanoma or non-skin cancer in the past 3 yearsa
Intolerance to lactose
Significant haematological or biochemical abnormality:
Haemoglobin ≤8.5 g/dL
WCC ≤3.5 × 109/L
Neutrophils ≤1.5 × 109/L
Platelets ≤100 × 109/L
ALT >2 times ULN for the laboratory conducting the test.
Creatinine >1.5 times ULN for the laboratory conducting the tested
eGFR <30 mL/minute
aCriteria for which participants may be rescreened if they are ineligible at the initial screening visit. ALT, alanine aminotransferase; COPD, chronic obstructive
pulmonary disease; eGFR, estimated glomerular filtration rate; IA, intra-articular; IM, intramuscular; IV, intravenous; RA, rheumatoid arthritis; ULN, upper limit of
normal; VAS, visual analogue scale; WCC, white cell count.
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Randomisation
Knee pain / NRS / pain manikins 
WOMAC / ICOAP
OA QoL / HADS/ EQ-5D / SF-12/ Resource use 
Concomitant meds
At 6/52 increase MTX/placebo to 25mg weekly
At 4/52 increase MTX/placebo to 20mg weekly 
Adverse events / concomitant meds 
At 2/52 increase placebo to 15mg weekly
Knee pain / NRS / pain manikins
WOMAC / ICOAP
OA QoL / HADS / EQ-5D / SF-12/ Resource use
Brief medication / adverse events / concomitant meds 
Summary of trial
PIS given and trial explained.
Patient given at least 24 h to decide whether 
they would like to enter the study
Informed consent gained
Bloods, urinalysis and pregnancy monitoring 
Chest & knee X-rays
Demographic and physical examination recorded
Patients meeting inclusion criteria recruited
Visit 1 Screening  
(-1 month/4 weeks)
Start placebo 10mg weekly & folic acid  
5mg six days a week
Visit 3 ± 10 days
(1 month/4 weeks)
Visit 2 Baseline  
(0 months)
Knee pain / NRS / pain manikins 
WOMAC / ICOAP
OA QoL / HADS / EQ-5D / SF-12 / Resource use
Brief medication / adverse events / concomitant meds 
Follow-up as per routine NHS care
Visit 4 ± 10 days
(2 months/8 weeks)
Knee pain / NRS / pain manikins 
WOMAC / ICOAP
Brief medication / adverse events / concomitant meds 
Visit 5 ± 21 days 
(3 months/12 weeks)
Visit 6 ± 21 days
(6 months/24 weeks)
Visit 7 ± 21 days 
(9 months/36 weeks)
Visit 8 ± 21 days 
(12 months/48 weeks)
Knee pain / NRS / pain manikins
WOMAC / ICOAP
Brief medication / adverse events / concomitant meds 
Telephone call ± 21 days
(13 months/52 weeks) Adverse events
Adverse events / concomitant meds 
At 2/52 increase MTX to 15mg weekly
Start MTX 10mg weekly& folic acid  
5mg six days a week
Knee MRI
Biological substudy bloods
Knee examination
Figure 2 Participant flowchart. EQ-5D, EuroQol 5D-5 L; HADS, hospital anxiety and depression scale; ICOAP, intermittent and constant
osteoarthritis pain scale; MRI, magnetic resonance imaging; MTX, methotrexate; NHS, National Health Service; NRS, numerical rating scale; OA QoL,
osteoarthritis quality of life; PIS, patient information sheet; SF-12, Short Form-12; WOMAC, Western Ontario and McMaster Osteoarthritis Index.
Treatment assignment and allocation concealment.
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during the trial. At the baseline visit, medical history
and demographic data, including smoking and alcohol
consumption, employment and family history of knee
OA will be collected. Physical examination and vital
signs, including height and weight, will be collected at
screening, six and 12 months. A clinical examinationof the knee will also be conducted at the baseline visit.
This will assess effusion on a zero to three scale,
where one is positive bulge sign, two is positive
fluctuance (balloon sign) and three is tense effusion,
and compartmental (medial tibiofemoral (MTF), lat-
eral tibiofemoral (LTF) or patellofemoral (PF)) ten-
derness, also measured on a zero to three scale. The
Kingsbury et al. Trials  (2015) 16:77 Page 10 of 14specific tools used to capture each data element are
further detailed in Table 2.
Safety assessments
Adverse events will be recorded throughout the study.
Intensity and relationship to the study medication will
be ascribed.
Blood and urine safety assessment
Safety of therapy will be assessed according to regional
monitoring guidelines and will be determined by treat-
ment strategy. Full blood count (FBC), liver function test
(LFT) and urea and electrolytes (U&E) tests will be per-
formed at screening, every two weeks for the first eight
weeks, and every four weeks thereafter. If a patient’s re-
sults remain abnormal despite action (such as reducing
their MTX dose), or at clinician discretion, then study
medication will be stopped. For the purposes of this
study, abnormal is defined as: haemoglobin ≤8.5 g/dL;
white cell count (WCC) ≤3.5 × 109/L; neutrophils ≤1.5 ×
109/L; platelets ≤100 × 109/L; alanine aminotransferase
(ALT) > two times the upper limit of normal (ULN) for
the laboratory conducting the test; creatinine >1.5 times
the ULN for the laboratory conducting the test and esti-
mated glomerular filtration rate (eGFR) <30 mL/minute.
C-reactive protein (CRP), anti-cyclic citrullinated pro-
tein (anti-CCP) and rheumatoid factor (RF) tests will be
performed at screening. Anti-CCP and RF results from
the previous 12 months may be used if these are available.
A dipstick urinalysis will be performed at screening to
check for evidence of leucocytes, blood or protein, to ex-
clude urine infection. A urine dipstick pregnancy test will
be performed for female participants with child-bearing
potential, and appropriate contraceptive methods docu-
mented for those at risk.
Data integrity and management
All data obtained will be kept strictly confidential and
will be stored electronically on a database with secured
and restricted access. Datasets for each subject will be
identified by the participant trial identification number
only.
Withdrawal
All participants have the right to withdraw consent at
any time without prejudice. At the time of withdrawal of
consent, a full efficacy and safety evaluation should be
performed if the participant consents. Participants who
withdraw will be asked to complete the questionnaires
as per the next planned study visit. At a participant’s re-
quest, their data collected up to the point of withdrawal
can also be withdrawn from the trial and will not be
used in the final analysis. Participants who withdraw willreturn to routine care in the rheumatology and musculo-
skeletal out-patient clinics.
In the event that a patient is unable to tolerate 7.5 mg
of MTX, they will be withdrawn from treatment but will
continue to be followed up on as per the planned
follow-up schedule, unless they request to fully withdraw
from the trial.
Study site staff training
A centralized introduction and training session was held
for all principal investigators and site staff. In addition to
this, a site initiation visit will be held at all sites, in order
to provide specific training to all staff involved in the
study ahead of recruitment. Pre-study training will be
conducted to ensure robustness of MRI acquisition.
Trial site monitoring
The trial will be overseen and monitored by the York
Trials Unit on behalf of the Sponsor, the University of
Leeds. Each site will be assessed prior to site setup, and
visited again once the third participant is recruited or at
20 weeks after the start of recruitment at site, whichever
is sooner. The PROMOTE trial was assessed as low risk
by the Medicines and Healthcare Products Regulatory
Agency (MHRA), and therefore in addition to the single
monitoring visit, procedures for central monitoring at
the clinical trials unit have been put in place. This will
mainly involve cross-checking logs returned from the re-
search team and site pharmacy for consistency. A data
monitoring and ethics committee will provide independ-
ent oversight to ensure data quality and compliance with
the trial protocol.
Statistical analysis
Full details of the statistical methods will be written in
an approved statistical analysis plan prior to any data
analysis.
Primary endpoint analysis
The primary analysis will be conducted on the intention-
to-treat population, including all randomized participants
in the groups to which they were randomized. A per
protocol population (excluding major protocol violations)
will be used to check the robustness of the primary ana-
lyses. The safety population will consist of all patients re-
ceiving at least one dose of the study drug.
The first 30 participants (included in the internal pilot
study) will be included in the main trial analysis along
with the rest of the participants. Wittes and Brittain
show that sample size re-estimation using an internal
pilot study has minimum impact on the overall type I
error, therefore an alpha level of 0.05 will still be used
for the primary analysis [57].
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primary outcome data becomes available for the thirtieth
participant, will include the following:
1. Assessment of the variability of the primary
outcome measure, the estimate (SD) will be used to
update the sample size calculation;
2. Consent rate (out of the number of information
packs sent out during the pilot phase);
3. Retention rates associated with each treatment and
4. Return rate for the six-month outcome assessment.
The primary analysis for the main study will be con-
ducted using linear regression adjusting for the baseline
measure. Treatment groups will be compared at six
months with respect to their average overall knee pain
severity over the previous week.
All secondary analyses will be conducted using linear
or logistic regression, depending on the type of outcome
measure, adjusting for the same covariates as the pri-
mary analysis. The intention-to-treat population will be
used for all secondary analyses. All secondary outcomes
will be described descriptively (mean, SD, median, mini-
mum and maximum for continuous data and counts and
percentages for categorical data). The Short Form-12
questionnaire will be summarized for all components.
To minimise multiple testing, only the overall physical
component score and mental component score will be
analysed, using the same analysis methods as for the pri-
mary outcome. For continuous outcomes the regression
model assumptions will be checked and, if necessary,
data will be transformed prior to analysis if this im-
proves the model fit, or normalises the distribution of
residuals.
Adverse events will be coded according to the Med-
DRA adverse event dictionary. The overall incidence of
serious adverse events and adverse events and number
and proportion of patients reporting such events will be
summarized by treatment group. Adverse events (includ-
ing serious adverse events) will be summarized by the
number and percentage of subjects who experienced the
event by system organ class and preferred term. Subjects
will only be counted once. If a subject reports the same
adverse event more than once then the maximum grade
and strongest causal relationship to study treatment will
be used for the summary tables. Adverse events will also
be summarized by severity and by relationship to study
drug. All adverse events will be included in individual
subject line listings.
Analysis of MRI endpoints will be exploratory. Treat-
ment groups will be compared with respect to changes
in synovitis, cartilage and bone using linear regression
models with adjustment for the same covariates as the
primary analysis. Linear regression models will also beused to explore the association between symptom out-
come and baseline MRI measurements. Changes in MR
features and the relationship of these changes with
symptom changes will be explored descriptively.
Health economics analysis
An economic analysis will be undertaken in order to de-
termine the cost-effectiveness of oral MTX for the treat-
ment of knee OA. A cost-utility analysis will also be
undertaken to explore the impact on health-related qual-
ity of life. The analyses will be conducted from the per-
spective of the United Kingdom NHS and Personal
Social Services (PSS), in line with National Institute for
Health and Care Excellence recommendations [58].
Health benefits for the economic evaluation will be
measured in terms of pain reduction and QALYs. The
QALY is a generic outcome which enables decision
makers to compare across different disease areas. QALYs
will be generated from the EuroQol EQ-5D-5 L for use
in the cost-utility analysis, and will be estimated by
measuring the area under the curve [59]. Utility data will
be collected at the same time points as for clinical out-
comes (at baseline, six months and 12 months).
Costs of the intervention, control and the total health
care costs during the treatment and follow-up period
will be assessed, including costs of adverse events and
medications. Health service resource use will be col-
lected via a self-reported resource use questionnaire,
with national costs applied to the quantities of resources
utilized, for example using NHS Reference Costs [60]
and Unit Costs of Health and Social Care [61]. The unit
costs of medications will be sourced from the British
National Formulary [62].
The within-trial analysis will use regression methods
to allow for the correlation between cost and outcome
data generated from the trial, with adjustment for covar-
iates. A cost-effectiveness analysis will determine the
cost per unit of reduction in knee pain score (as mea-
sured on the NRS). A cost-utility analysis will be under-
taken to generate the cost per QALY. The results will be
presented in terms of incremental cost-effectiveness ra-
tios (ICERs). Future costs and outcomes will not be
discounted due to the trial follow-up being one year.
Cost-effectiveness acceptability curves will be produced
to explore the probability that MTX will be cost-
effective at different cost-effectiveness thresholds [63].
Discussion
Current medical therapy does not provide satisfactory
pain relief in the majority of people with OA [64]; with
the rapidly ageing population the prevalence of OA will
continue to rise over the next decade. Unless the bar-
riers to successful treatment of OA are overcome, the
already considerable social and economic burden will
Kingsbury et al. Trials  (2015) 16:77 Page 12 of 14soon reach an unsustainable level. The last decade has
seen major advances in understanding OA pathology.
MRI has demonstrated that synovial inflammation is
common in OA and is related to symptoms. MTX is the
most common agent used to treat synovitis in RA and
because of its favourable efficacy, long-term retention
rates, low cost and established track record it has be-
come the standard by which other DMARDs are evalu-
ated, supporting our choice to use MTX rather than any
other DMARD for a trial in OA. Since the design of this
study and conduct of the systematic literature review, a
single-centre randomized controlled trial of MTX in
knee OA has been published [65]. The study demon-
strated a clinically relevant reduction in knee pain and
physical function in the intervention group compared
with the placebo group at 28 weeks. A significantly
higher proportion of patients in the MTX group (53%)
showed a reduction in VAS of more than 20 mm com-
pared to the placebo group (24%; P = 0.018). The positive
findings of this study reinforce the potential of MTX as
a treatment for OA. However, given the substantial im-
pact that using MTX for treating OA would have on
clinical practice, a large multi-centre confirmatory study
is essential. The PROMOTE trial has been designed to
be pragmatic in nature so as to answer the question as
to whether MTX is a valuable addition to the overall
management of patients with OA.Trial status
Recruitment to the trial began in June 2014. Follow-up
of participants is in progress and is expected to be com-
pleted in December 2016.
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